Risk reduction is a measure of how much a treatment, vaccine, or intervention lowers your chance of experiencing a bad outcome compared to doing nothing. It’s one of the most important concepts in health decision-making, but the way it’s expressed can dramatically change how effective a treatment appears. The same intervention can sound like it cuts your risk by 60% or by just 1.4%, depending on which type of risk reduction is being reported. Understanding the difference helps you evaluate health claims with clear eyes.
Two Types of Risk Reduction
There are two fundamentally different ways to express how well a treatment works: absolute risk reduction and relative risk reduction. They use the same data but tell very different stories.
Absolute risk reduction (ARR) is the straightforward difference between two groups. If 20 out of 100 untreated people get sick, and 12 out of 100 treated people get sick, the absolute risk reduction is 8 percentage points (20% minus 12%). This tells you the actual size of the benefit in real-world terms.
Relative risk reduction (RRR) expresses that same benefit as a proportion of the original risk. In the example above, the treatment reduced the 20% risk by 8 points, which is 40% of 20. So the relative risk reduction is 40%. That number sounds far more impressive, even though it describes the exact same outcome. Relative risk reduction is calculated by dividing the absolute risk reduction by the risk in the untreated group.
Why the Distinction Matters
The gap between these two numbers creates real problems for decision-making. In a landmark study on how patients perceive treatment benefits, 56.8% of patients chose a medication when its benefit was framed in relative terms, while only 14.7% chose the same medication when the benefit was presented in absolute terms. This preference held across all ages and education levels. Further questioning revealed the reason: patients who saw relative numbers tended to ignore the underlying risk of disease entirely and assumed it was higher than it actually was.
This “framing effect” isn’t just an academic curiosity. It shapes how drugs are marketed, how vaccines are discussed, and how you weigh the pros and cons of medical decisions. A treatment that offers a 50% relative risk reduction sounds like it works half the time. But if your baseline risk was only 2%, that 50% reduction means your risk dropped from 2% to 1%, an absolute reduction of just 1 percentage point.
Real-World Examples
Statins offer one of the clearest illustrations of how baseline risk changes the picture. In patients with heavy coronary artery plaque buildup, statins provided a 44% relative risk reduction in cardiovascular events and an 8.5% absolute risk reduction over 12 years. That’s a meaningful, tangible benefit. But in patients with no detectable plaque, the absolute risk reduction was only 1.1%, and the relative benefit was negligible. Same drug class, vastly different real-world impact depending on how much risk you started with.
Flu vaccines show the same pattern. A large meta-analysis of 52 studies covering 80,000 healthy adults found that the influenza vaccine had a 59% relative risk reduction for flu infection. That sounds excellent. But because the baseline risk of getting the flu in any given season is already low (about 2.3% in the unvaccinated group), the absolute risk reduction was only 1.4%, dropping infection rates from 2.3% to 0.9%.
Neither number is wrong. The 59% figure accurately describes how much the vaccine reduces your chances relative to your starting risk. The 1.4% figure accurately describes how many people, in absolute terms, are spared infection. But they paint very different mental pictures, and you need both to make an informed judgment.
How Baseline Risk Changes Everything
A consistent finding across medical research is that relative risk reduction tends to stay roughly the same regardless of how high or low your starting risk is. What changes is the absolute benefit. If a drug cuts risk by 40% whether your baseline risk is 4% or 40%, the absolute benefit ranges from 1.6 percentage points to 16 percentage points. The higher your starting risk, the more you personally stand to gain from the intervention.
This is why doctors consider your individual risk profile before recommending treatments. A blood pressure medication with a 30% relative risk reduction makes a bigger real-world difference for someone with a 25% chance of a heart attack over the next decade than for someone with a 3% chance. For the high-risk person, the absolute benefit is large enough to clearly outweigh side effects. For the low-risk person, the math is less obvious.
Number Needed to Treat
One of the most practical tools for understanding risk reduction is the number needed to treat (NNT). It answers a simple question: how many people need to receive this treatment for one person to benefit? You calculate it by dividing 1 by the absolute risk reduction.
If an anti-nausea drug reduces post-surgical nausea from 40% to 15%, the absolute risk reduction is 25%, and the NNT is 4. That means for every 4 patients treated, 1 is spared nausea. That’s a strong result. Compare that to the statin example in patients with no plaque: the NNT there was 92, meaning you’d need to treat 92 low-risk patients for one to avoid a cardiovascular event.
NNT makes it easy to compare treatments across completely different conditions. A lower NNT means the treatment has a bigger practical impact per person treated. It also exposes a common illusion: two treatments can have identical relative risk reductions but wildly different NNTs. Consider two scenarios where a treatment cuts risk by 37.5% in both cases. If the untreated group’s risk is 40%, the NNT is 7. If the untreated group’s risk is 4%, the NNT is 67. Same relative reduction, but in one case you’re treating 7 people to help one, and in the other you’re treating 67.
How to Read Health Claims More Clearly
When you encounter a claim that a treatment “reduces risk by X%,” your first question should be: is that relative or absolute? If the article or advertisement only reports relative risk reduction, that’s a red flag for incomplete information. Current medical publishing standards recommend that researchers report absolute risk reduction alongside relative figures, precisely because relative numbers alone can be misleading.
Three pieces of information give you the full picture:
- Baseline risk: what is the chance of the bad outcome without the treatment?
- Absolute risk reduction: by how many percentage points does the treatment lower that chance?
- Number needed to treat: how many people need to use this treatment for one person to benefit?
With those three numbers, you can evaluate any health intervention on your own terms. A 78% relative risk reduction sounds transformative, but if the baseline risk was 5%, the absolute reduction is about 3.9 percentage points and the NNT is roughly 26. Whether that’s worth it depends on the severity of the outcome being prevented, the cost and side effects of the treatment, and your own starting risk. Risk reduction isn’t just a number. It’s a calculation that only makes sense in the context of your own situation.